September 15, 2025

Ademi Firm Investigates Corporations for Fiduciary Violations

here-intlog
September 15, 2025
6:38 am
Milwaukee

News Summary

The Ademi Firm is investigating several corporations, including BankFinancial and CARGO Therapeutics, for potential fiduciary duty violations related to recent merger transactions. The investigations focus on whether these companies’ boards have adequately protected shareholders, particularly concerning insider benefits and restrictions on competing bids. With significant shareholder impacts anticipated, the firm is urging affected individuals to engage in the process without obligations.

Milwaukee, WI – The Ademi Firm is launching investigations into multiple corporations for potential violations of fiduciary duty and other legal issues related to recent merger transactions that could impact shareholders negatively. Four companies are currently under scrutiny, including BankFinancial Corporation, CARGO Therapeutics, Inc., Sapiens International Corporation, and Dayforce Inc.

In the case of BankFinancial Corporation (Nasdaq: BFIN), the firm is specifically examining a transaction with First Financial Bancorp. This all-stock deal, valued at approximately $142 million based on the stock price from August 8, will provide BankFinancial shareholders with 0.48 shares of First Financial common stock. The investigation seeks to determine if the BankFinancial board has adequately fulfilled its fiduciary responsibilities to all shareholders, especially considering that insiders will receive substantial benefits under change of control arrangements. Additionally, the transaction agreement includes clauses that restrict competing bids by imposing heavy penalties should BankFinancial consider an alternative offer.

In another investigation, the Ademi Firm is scrutinizing CARGO Therapeutics, Inc. (NASDAQ: CRGX) in relation to its deal with Concentra Biosciences. Shareholders of CARGO are set to receive $4.379 per share in cash and a non-transferable contingent value right tied to future earnings from select product candidates. Similar to the arrangements observed in BankFinancial, insiders at CARGO will also enjoy notable benefits. Furthermore, their transaction agreement restricts competing proposals and includes penalties for contemplating alternative bids, prompting concerns regarding the board’s adherence to fiduciary duties.

Another company under investigation is Sapiens International Corporation (Nasdaq: SPNS), which has finalized an agreement with Advent. In this transaction, Sapiens shareholders are offered $43.50 per common share, amounting to approximately $2.5 billion. Interestingly, Formula Systems (1985) Ltd., a shareholder of Sapiens, will retain its stake following the merger. The change of control arrangements will reportedly benefit insiders as well, and much like the previous transactions, the agreement includes restrictions against competing offers, imposing significant penalties for accepting other proposals. This raises further questions about whether Sapiens’ board is fulfilling fiduciary responsibilities to its shareholders.

Dayforce Inc. (NYSE: DAY) is also part of the growing list of investigations, regarding its acquisition by Thoma Bravo. Dayforce shareholders will receive a substantial $70.00 per share in an all-cash transaction valued at approximately $12.3 billion. Similar to other cases, the deal includes substantial benefits for insiders associated with the change of control. Additionally, the transaction contract restricts competing bids and includes stiff penalties for considering alternative offers, again leading to inquiries about the board’s actions concerning fiduciary duties to shareholders.

The Ademi Firm specializes in litigation concerning shareholder rights, particularly in the realm of mergers and buyouts. Their focus centers around ensuring that corporate boards uphold their fiduciary duties and make decisions that are in the best interest of all shareholders involved.

Individuals who are interested in learning more about these investigations or wish to participate can contact the Ademi Firm through email or a toll-free phone number. There are no costs or obligations for those who choose to engage in the process.